Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $21.8052W HIGH $39.70
Volume
11.20 K
Value Traded
2.82 M
Short % Float
14.36%
+1.24%Week
-30.57%1 Month
-16.72%3 Month
-19.7%6 Month
-41.97%5 Year
-93.87%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
473.18 M
EPS (TTM)
-1.16
P/E Ratio
-
Ent. Value
144.27 M
Total Shares
20.36 M
Float Shares
14.59 M
Insiders
28.37%
Institutions
67.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ASMB Catalyst Timeline
Dated clinical, regulatory and corporate events for Assembly Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Assembly Biosciences, Inc.
707Total events
15Upcoming
144Tier-1 (high impact)
2011 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Assembly Bio exercises option to share 40% of U.S. development costs and profits for HSV HPI program with Gilead
recurrent genital herpessource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
◆Timing GuidancePresentation
Gilead's development plan and budget for herpesvirus program; opt-in decision by mid-2026
◆Poster PresentationABI-6250Presentation
Poster presentation of topline Phase 1a data on ABI-6250 at EASL Congress 2026
hepatitis delta virus (HDV)source ↗
▼Equity OfferingCorporate
Closing of underwritten registered offering of common stock and pre-funded warrants with full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of $100 million offering of common stock and pre-funded warrants
▲Trial CompletionABI-6250Trial
Phase 1a clinical trial completed in healthy participants
healthy participantssource ↗
◆Pre IND MeetingABI-6250FDA Meeting
Pre-IND meeting with FDA for ABI-6250 in cholestatic liver diseases
cholestatic liver diseases (PBC and PSC)source ↗
◆Oral PresentationPresentation
Presentation at BofA Securities 2026 Global Health Care Conference
◆Late-BreakerABI-1179Presentation
Late-breaker poster presentation on interim results from Phase 1b study of ABI-1179 at ESCMID Global 2026
recurrent genital herpessource ↗
◆Oral PresentationABI-5366Presentation
Oral presentation of Phase 1b data for ABI-5366 at ESCMID Global 2026
recurrent genital herpessource ↗
◆Poster PresentationABI-5366Presentation
Poster presentation on virologic analyses following treatment with ABI-5366 at ESCMID Global 2026
recurrent genital herpessource ↗
◆Trial InitiationABI-5366Trial
Initiation of Phase 2 clinical studies of ABI-5366 expected in mid-2026
recurrent genital herpessource ↗
▲Trial CompletionABI-6250Trial
Completed chronic toxicology studies for ABI-6250
chronic hepatitis delta virussource ↗
▲Partnership / LicenseABI-5366Corporate
Licensed helicase-primase inhibitor program to Gilead
recurrent genital herpessource ↗
▲Partnership / LicenseABI-1179Corporate
Licensed helicase-primase inhibitor program to Gilead
recurrent genital herpessource ↗
▲Interim AnalysisABI-1179Trial
Positive interim Phase 1b results for ABI-1179 weekly oral dosing
recurrent genital herpes (HSV-2)source ↗
▲Interim AnalysisABI-5366Trial
Positive interim Phase 1b results for ABI-5366 monthly oral dosing
recurrent genital herpes (HSV-2)source ↗
◆Topline ReadoutABI-5366Clinical Data
Additional interim Phase 1b data for ABI-5366 monthly oral dosing cohort
recurrent genital herpessource ↗
◆Topline ReadoutABI-1179Clinical Data
Additional interim Phase 1b data for ABI-1179 two cohorts of weekly oral dosing
recurrent genital herpessource ↗
◆Oral PresentationPresentation
Guggenheim 2nd Annual Healthcare Innovation Conference fireside chat
▲Topline ReadoutABI-5366Clinical Data
Positive Phase 1b interim results for ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate
recurrent genital herpessource ↗
▲Topline ReadoutABI-6250Clinical Data
Phase 1a interim results for ABI-6250 supporting progression into Phase 2
HDV infectionsource ↗
▲Enrollment CompleteABI-5366Trial
Enrollment completed in Phase 1b study for ABI-5366
recurrent genital herpessource ↗
▲Enrollment CompleteABI-1179Trial
Enrollment completed in two cohorts of Phase 1b study for ABI-1179
recurrent genital herpessource ↗
▲Oral PresentationABI-4334Presentation
Late-breaking poster presentation of Phase 1b data for ABI-4334 at AASLD The Liver Meeting
chronic hepatitis B infectionsource ↗
◆Oral PresentationPresentation
H.C. Wainwright Liver Disease Virtual Conference fireside chat
◆Oral PresentationABI-5366Presentation
Late-breaking oral presentation of interim Phase 1b data for ABI-5366 at IUSTI-Europe 2025
recurrent genital herpessource ↗
◆Topline ReadoutABI-5366Clinical Data
Interim data for monthly dosing regimen of ABI-5366 expected later this fall
recurrent genital herpessource ↗
◆Topline ReadoutABI-1179Clinical Data
Interim data for weekly dosing of ABI-1179 expected later this fall
recurrent genital herpessource ↗
●Oral PresentationABI-6250Presentation
Abstract describing preclinical profiling of ABI-6250 accepted for oral presentation at International HBV Meeting
chronic hepatitis delta virus (HDV)source ↗
▼Equity OfferingCorporate
Pricing of $175 million equity offering including common stock and warrants
▲Topline ReadoutABI-5366Clinical Data
Positive interim Phase 1b results for ABI-5366 350 mg weekly dose showing 94% reduction in HSV-2 shedding rate, 98% reduction in high viral load shedding rate, and 94% reduction in genital lesion rate
recurrent genital herpessource ↗
◆Interim AnalysisABI-6250Trial
Interim Phase 1a data reported for ABI-6250
hepatitis delta virussource ↗
▲Enrollment CompleteABI-6250Trial
Dosing complete in two single-dose and three multiple-dose cohorts
hepatitis delta virussource ↗
▲Enrollment CompleteABI-5366Trial
Enrollment completed for cohorts B1 and B2 (150/30 mg and 350 mg) of Phase 1b study
recurrent genital herpessource ↗
●Poster PresentationABI-5366Presentation
Preclinical profile and interim Phase 1a safety/PK data for ABI-5366 at International Herpesvirus Workshop
recurrent genital herpessource ↗
●Poster PresentationABI-1179Presentation
Late-breaking poster for ABI-1179 Phase 1a data at STI & HIV 2025 World Congress
recurrent genital herpessource ↗
●Oral PresentationABI-1179Presentation
Oral presentation on preclinical profile and interim Phase 1a safety/PK data for ABI-1179 at International Herpesvirus Workshop
recurrent genital herpessource ↗
●Oral PresentationABI-5366Presentation
One oral and one poster presentation at 49th Annual International Herpesvirus Workshop
recurrent genital herpessource ↗
Past FDA Catalysts and PDUFA Decisions
How ASMB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-27 | ABI-6250 | Phase 1a interim results | Phase 1a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$114M
Pipeline Value
Overvalued
Valuation Signal
8
Drugs Scored
0.3x
rNPV / MCap
Top 59%
Micro Cap(rank 389 of 658)
Percentile Rank
Assembly Biosciences, Inc. faces pipeline headwinds (33/100), with $286M risk-adjusted pipeline value, led by ABI-H0731 in Chronic Hepatitis B (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABI-H0731 Small moleculeCompletedNCT03109730 | Chronic Hepatitis B | Phase 2 | COMPLETED | 222 | Jun 12, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every ASMB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ABI-6250 | chronic HDV infection and cholestatic liver diseases | Phase 1a | 2026-10-05 | ABI-6250 was well tolerated at the doses evaluated, with no serious adverse events reported; demonstrated dose-dependent, reversible increases in total and conjugated bile acids consistent with sodium taurocholate co-transporting polypeptide (NTCP) target engagementRead More | Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bjorkquist Jeanette MOfficer (PFO and PAO) | Sell | -29 14,560 held | $23.25 | 06/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ASMB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 0.8 % (100 %) | 42.70 M | 1.55 M | 133.56% ( 888.50 K) |
ASMB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ASMB ranks across every disease it competes in
Competitive Position is a premium feature
See how ASMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialASMB News
ASMBAssembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
Assembly Biosciences announced positive Phase 1a data for ABI-6250, indicating its safety and target engagement. The findings will be presented at The Liver Meeting 2026, with plans to advance to Phase 2 studies for chronic HDV infection and cholestatic liver diseases. The drug was well tolerated in healthy participants, showing promising results.
Read more →ASMBAssembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
Assembly Biosciences will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference on September 16, 2026. The presentation will focus on their innovative therapeutics for serious viral and liver diseases. A live webcast will be available, with a replay accessible afterward. The company emphasizes its commitment to improving patient outcomes.
Read more →ASMB▼ -6.8%on this news· ran to -18% by day 3shared move
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
Assembly Biosciences has exercised its option to share 40% of U.S. development costs and profits for its HSV helicase-primase inhibitor program with Gilead Sciences. This collaboration allows Assembly Bio to receive up to $280 million in milestones and royalties. The program is expected to advance into Phase 2 trials by the end of 2026, with a cash runway projected into 2029.
Read more →ASMB▲ +10%on this news
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
Assembly Biosciences reported significant advancements in its pipeline during Q2 2026, including the expansion of ABI-6250 into cholestatic liver diseases and the initiation of GS-1179 into a Phase 2 trial by year-end 2026. The company successfully completed a $115 million financing to support these developments. With a cash runway projected into 2029, Assembly Bio is well-positioned for future growth despite ongoing risks associated with clinical approvals.
Read more →ASMBAssembly Biosciences Announces Upcoming June 2026 Investor Conference Presentations
Assembly Biosciences announced that its senior management will participate in fireside chats at two upcoming investor conferences: Jefferies 2026 Global Healthcare Conference on June 3, 2026, and Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The company is dedicated to developing therapeutics for serious viral and liver diseases. A replay of the webcasts will be available after each event.
Read more →ASMBAssembly Biosciences Announces Upcoming Investor Conference Presentations
Assembly Biosciences announced that its senior management will participate in fireside chats at two upcoming investor conferences: the Jefferies 2026 Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. These events aim to enhance investor engagement and showcase the company's commitment to developing therapeutics for serious viral and liver diseases.
Read more →ASMBAssembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Assembly Biosciences has successfully closed its underwritten offering of 3,924,624 shares of common stock, raising approximately $115 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The funds will be utilized for clinical development and general corporate purposes. The company faces risks related to collaboration benefits and clinical study timelines.
Read more →ASMB▲ +6.9%on this newsshared move
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Assembly Biosciences is expanding the clinical development of ABI-6250 into cholestatic liver diseases, specifically targeting primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). This follows a completed Phase 1a study and aims to address significant unmet medical needs in these conditions. The company plans to initiate a Phase 2 study in Q1 2027, pending regulatory feedback.
Read more →ASMB▲ +6.9%on this newsshared move
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
Assembly Biosciences has announced the pricing of a $100 million offering of common stock and pre-funded warrants. The offering includes 3,358,602 shares priced at $26.50 each, with participation from significant investors such as Gilead Sciences. Proceeds will support clinical development and general corporate purposes, with the offering expected to close by May 26, 2026.
Read more →ASMBAssembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
Assembly Biosciences announced that it will present topline Phase 1a data on ABI-6250, an oral hepatitis D virus entry inhibitor, at the EASL Congress 2026. The data will support the company's plan to advance into a Phase 2 study by the end of the year. The presentation will cover safety, pharmacokinetics, and pharmacodynamics from a randomized, blinded study.
Read more →ASMBAssembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
Assembly Biosciences, a biotechnology firm, announced that its Chief Medical Officer, Anuj Gaggar, will present at the Bank of America Securities 2026 Global Health Care Conference on May 13, 2026. The presentation will focus on the company's innovative therapeutics aimed at serious viral diseases. A live webcast of the event will be available on their website.
Read more →ASMBAssembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Assembly Biosciences reported its first quarter 2026 financial results, highlighting the completion of Phase 1b studies for ABI-5366 and ABI-1179, as well as chronic toxicology studies for ABI-6250. The company anticipates initiating Phase 2 for ABI-6250 by Q4 2026. CEO Jason Okazaki noted ongoing progress and plans to evaluate Gilead's development plan for their herpesvirus program by mid-2026.
Read more →ASMBAssembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
Assembly Biosciences announced positive Phase 1b clinical data for ABI-5366 and ABI-1179, which are HSV helicase-primase inhibitors for recurrent genital herpes. The data will be presented at the ESCMID Congress in April 2026, with ABI-5366 featured in an oral presentation. ABI-1179's data will be presented as a late-breaker poster, highlighting its potential as a long-acting treatment.
Read more →ASMBAssembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
Assembly Biosciences reported its year-end 2025 financial results, highlighting a successful licensing agreement with Gilead for its helicase-primase inhibitor program following positive Phase 1b data. The company anticipates initiating Phase 2 trials for ABI-6250 by the end of 2026. CEO Jason Okazaki expressed optimism about the company's scientific and financial positioning for 2026.
Read more →ASMBAssembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences reported positive interim results from Phase 1b studies on two investigational helicase-primase inhibitors, ABI-1179 and ABI-5366, for treating recurrent genital herpes. ABI-1179 showed a 98% reduction in HSV-2 shedding and a 91% reduction in genital lesion rates. ABI-5366 also demonstrated significant antiviral activity with 76% reduction in virus shedding. Both treatments were found to be well-tolerated, paving the way for potential Phase 2 trials in the future.
Read more →ASMBAssembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
Assembly Biosciences reported strong third quarter results, highlighting positive interim data for ABI-5366 in treating recurrent genital herpes and the advancement of ABI-6250 to Phase 2 trials. The company raised $175 million in equity financing to support its pipeline. Additional data from ongoing studies is expected by year-end.
Read more →ASMBAssembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
Assembly Biosciences presented positive Phase 1b data for ABI-4334 at AASLD, showcasing its safety and potent antiviral effects against hepatitis B. The study reported significant declines in viral nucleic acids, indicating the drug's effectiveness. ABI-4334 is being evaluated in collaboration with Gilead Sciences for further development.
Read more →ASMBAssembly Biosciences Announces Upcoming Investor Conference Participation
Assembly Biosciences, Inc. (ASMB) announced its participation in two upcoming investor conferences. Chief Medical Officer Anuj Gaggar will present at the H.C. Wainwright Liver Disease Virtual Conference, while CEO Jason Okazaki and Dr. Gaggar will speak at the Guggenheim 2nd Annual Healthcare Innovation Conference. Both events will feature pre-recorded fireside chats available for on-demand viewing.
Read more →ASMBAssembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
Assembly Biosciences presented interim Phase 1b data for ABI-5366, a novel HSV helicase-primase inhibitor, at the IUSTI Congress. The data showed significant reductions in HSV-2 shedding and genital lesions compared to placebo, indicating the drug's potential effectiveness. The company plans to advance ABI-5366 to Phase 2 studies by mid-2026.
Read more →ASMB▲ +13%on this news
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
Assembly Biosciences has announced the pricing of a $175 million equity financing, which includes the sale of shares and warrants. The offering involves participation from both new and existing investors, including Gilead Sciences. The proceeds will be used for general corporate purposes, and the offering is expected to close on August 11, 2025, pending customary conditions.
Read more →About Assembly Biosciences, Inc.
HeadquartersTWO TOWER PLACE, SOUTH SAN FRANCISCO, CA, 94080
Founded2005
BIOPHARMAWATCH ELITE PLUS
Trade the next ASMB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime